Smith & Nephew plc (LON:SN)

Market Cap	9.98B -16.2%
Revenue (ttm)	4.77B +6.0%
Net Income	480.47M +29.3%
EPS	0.56 +31.8%
Shares Out	837.03M
PE Ratio	21.43
Forward PE	13.09
Dividend	0.29 (2.45%)
Ex-Dividend Date	Oct 1, 2026

Volume	4,532,900
Open	1,086.00
Previous Close	1,117.50
Day's Range	1,082.00 - 1,194.00
52-Week Range	980.40 - 1,426.60
Beta	0.67
Analysts	Hold
Price Target	1,233.69 (+3.45%)
Earnings Date	Mar 1, 2027

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1856
• Employees: 17,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: SN

Financial Performance

In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.

Financial numbers in USD

Analyst Summary

According to 18 analysts, the average rating for SN stock is "Hold." The 12-month stock price target is 1,234p, which is an increase of 3.45% from the latest price.

Price Target

1,234p

(3.45% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 4, 2026

Data Sources Report a data error